ANI Pharmaceuticals, Inc.
ANIP
$82.10
-$0.57-0.69%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 211.35% | -45.48% | 252.60% | 57.48% | -956.67% |
| Total Depreciation and Amortization | -2.79% | 1.70% | 1.29% | 43.51% | 7.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 63.19% | 257.76% | -159.02% | -33.79% | 32.13% |
| Change in Net Operating Assets | -149.22% | 2,626.56% | 127.79% | -157.43% | 284.86% |
| Cash from Operations | -41.89% | 116.66% | 120.62% | 27.14% | -28.37% |
| Capital Expenditure | -52.04% | -62.25% | -3.34% | 50.25% | -8.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 97.91% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 97.93% | 83.34% | -20,100.00% | 86.37% | -- |
| Cash from Investing | 10.80% | 65.19% | -85.81% | 97.32% | -8,857.56% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | 0.00% | 0.00% | -1,201.92% | 99.95% | -39,150.00% |
| Issuance of Common Stock | 688.24% | -50.99% | 49.06% | 42.62% | 18.61% |
| Repurchase of Common Stock | -89.47% | 94.49% | -3,045.60% | 53.24% | 47.69% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 15.48% | -0.25% | 0.00% | 0.00% | 0.25% |
| Other Financing Activities | -- | -- | -- | 89.76% | -- |
| Cash from Financing | 463.19% | 82.36% | -101.87% | -101.69% | 20,143.39% |
| Foreign Exchange rate Adjustments | -31.51% | 383.16% | 24.81% | -426.67% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -34.10% | 1,275.90% | 4,117.89% | 99.87% | -925.96% |